Kyron.bio uses the power of glycan alterations to enable improved protein therapies.
Kyron.bio has raised $6.2M in total funding. The most recent round was Seed. The last funding was announced in May 2025.
Kyron.bio's investors include Entrepreneurs First, Verve Ventures, HCVC, European Innovation Council, Saras Capital.
Kyron.bio is headquartered in Faubourg Saint-jacques, France.
Kyron.bio uses the power of glycan alterations to enable improved protein therapies.
Kyron.bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kyron.bio — Funding & Investors." VCBacked, May 28, 2025, https://www.vcbacked.co/company/kyronbio. Accessed July 20, 2026.
VCBacked. (2025). Kyron.bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/kyronbio
{{cite web |title=Kyron.bio — Funding & Investors |url=https://www.vcbacked.co/company/kyronbio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated